Genentech Reports the P-III (METEOROID) Trial Data on Enspryng (Satralizumab) to Treat MOGAD

Why It Matters

These results position Enspryng as the first disease‑modifying therapy for MOGAD, a rare autoimmune neurological disorder with limited treatment options, potentially reshaping standard care and opening a new market for Genentech.

Key Takeaways

• Enspryng achieved 87% relapse‑free rate vs 67% placebo at 48 weeks.
• Annualized relapse rate fell 66% compared with placebo.
• MRI‑active lesions reduced 79% across optic nerve, brain, spinal cord.
• Rescue therapy need dropped 73% versus placebo.
• Inpatient hospitalizations decreased 17% numerically.

Pulse Analysis

MOGAD, or myelin oligodendrocyte glycoprotein antibody‑associated disease, is an increasingly recognized inflammatory demyelinating condition that can mimic multiple sclerosis and neuromyelitis optica. Patients experience recurrent optic neuritis, transverse myelitis, and brain lesions, often leading to permanent visual loss or disability. Until now, therapeutic options have been limited to off‑label use of steroids, plasma exchange, or broad immunosuppressants, which provide inconsistent control and carry significant side‑effect burdens. The lack of a targeted, disease‑modifying agent has left clinicians searching for more reliable solutions.

The Phase III METEOROID trial evaluated subcutaneous Enspryng at weight‑adjusted doses (60‑180 mg) administered on a loading schedule followed by monthly injections. Among patients 12 years and older, 87 % remained relapse‑free at 48 weeks compared with 67 % on placebo, and the benefit emerged within eight weeks. Secondary endpoints were equally striking: a 66 % reduction in annualized relapse rate, a 79 % cut in MRI‑active lesions across the optic nerve, brain and spinal cord, and a 73 % decline in rescue‑therapy use. Safety data were consistent with the drug’s known profile in neuromyelitis optica spectrum disorder.

Regulatory agencies are likely to view these data as a compelling case for an indication extension, potentially granting Enspryng the first approved therapy for MOGAD. For Genentech, the approval could unlock a niche but growing market estimated at several hundred million dollars annually in the United States, with additional upside in Europe and Asia where diagnostic awareness is rising. Investors will watch the forthcoming FDA submission closely, as success could reinforce Genentech’s leadership in antibody‑based neuro‑immunology and provide a template for future rare‑disease expansions.